GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-11-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objectives:

* To determine the effectiveness of the 3-month depot leuprolide in inducing and maintaining secondary amenorrhea in patients undergo hematopoietic stem cell transplantation.
* To determine the incidence of regained ovarian function manifested as spontaneous restoration of menstruation and normalization of hormonal level in patients after transplantation and discontinuation of long-acting leuprolide.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368

Multiple Myeloma Non-Hodgkin Lymphoma Hodgkin Disease +2 more

TERMINATED PHASE2

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641

Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia +2 more

TERMINATED PHASE2

Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

NCT02566395

Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia Myelodysplastic Syndrome +3 more

COMPLETED PHASE3

Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

NCT00038779

Leukemia Non Hodgkin's Lymphoma Aplastic Anemia

TERMINATED NA

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

NCT01338987

Myelodysplastic Syndrome Acute Lymphocytic Leukemia Acute Myelogenous Leukemia +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All participants in this study will be scheduled for hematopoietic stem cell transplantation at The University of Texas (UT) MD Anderson Cancer Center.

Within two months before the transplantation, all participants will have a medical history, physical exam, and blood tests for ovarian function and platelet count. Participants will also need to have a gynecologic exam within one year before the transplantation.

Participants who are eligible will receive the first dose of leuprolide as an injection into either the shoulder muscle or the thigh muscle during their first clinic visit. Participants who have low platelet count will be given platelet transfusion before the injection.

Participants will then go on to have the transplantation as scheduled. Three months after the first dose of injection participants will have another clinic visit where blood tests for ovarian function will be performed. A second dose of the leuprolide will be given as an injection into the muscle at this visit. Again, if patients have low platelet count at that time, platelet transfusion will be given to patients before the injection. Participants will be given a checklist sheet for them to record any side effects while on the effect of leuprolide.

Three months after the last dose of the injection, patients will have the option to start taking or to resume oral contraceptive pills. Those who choose not to take or to resume oral contraceptive pills will be followed and observed for the return of menstrual or monthly cycles. Those who choose to take or to resume oral contraceptive pills, has to stop taking oral contraceptive pills for a period of 3-6 months starting 1 year after transplantation for us to assess the ovarian function.

During the period of follow up and observation of the return of menstruation, participants will be seen every two months either in the clinic or in the hospital if they are admitted. Participants will fill out questionnaires about their menstrual history at these visits. They should take about 15 minutes to complete. Blood tests for the ovarian function will also be done during these visits.

This is an investigational study. The drug used in this study is commercially available and has been approved by FDA for use in prostate cancer patients. Its use in this study is investigational. About seventy-five patients will take part in this study. All will be enrolled at MD Anderson.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amenorrhea Premature Ovarian Failure Ovarian Function Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Leuprolide Acetate

Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.

Group Type EXPERIMENTAL

Leuprolide Acetate

Intervention Type DRUG

22.5 mg IM injection 2 months before transplant and 3 months post-transplant.

Questionnaire

Intervention Type BEHAVIORAL

Questionnaires taking about 15 minutes to complete.

Hematopoietic Stem Cell Transplantation

Intervention Type PROCEDURE

Stem cell infusion on Day 0.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Leuprolide Acetate

22.5 mg IM injection 2 months before transplant and 3 months post-transplant.

Intervention Type DRUG

Questionnaire

Questionnaires taking about 15 minutes to complete.

Intervention Type BEHAVIORAL

Hematopoietic Stem Cell Transplantation

Stem cell infusion on Day 0.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Leuprolide Acetate (delayed release) Lupron Depot Survey HSCT Stem Cell Transplant

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hematopoietic stem cell transplantation candidate.
* Post-menarche female less than 40 years old.
* Premenopausal before the start of transplantation, or the start of oral contraceptive pills.
* Follicle-stimulating hormone (FSH) less than or equal to 20 IU/L and Luteinizing hormone (LH) less than or equal to 20 IU/L within 1 weeks of initiation of injection or the ovarian status is determined by Gynecology Oncology Service.
* Agree to stop any oral contraceptive pills for a period of 3-6 months starting 1 year post-transplant